54.68 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||54.60 x 800|
|Ask||54.61 x 800|
|Day's Range||53.28 - 55.12|
|52 Week Range||39.01 - 67.79|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.44|
Patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating patients with obstructive hypertrophic cardiomyopathy (oHCM). Clinical site engagement remains high, and enrollment into the pivotal trial is expected to be completed by mid-August. MyoKardia now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of previous guidance of the second half of 2020.
MyoKardia, Inc. (MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This research is part of MyoKardia's efforts aimed at improving the detection, diagnosis and treatment of HCM, and holds the potential to help physicians more easily identify people who may be at risk of disease.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
While MyoKardia, Inc. (NASDAQ:MYOK) shareholders are probably generally happy, the stock hasn't had particularly good...
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in.
MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 93 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular.
SOUTH SAN FRANCISCO, Calif., May 02, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week.
The big shareholder groups in MyoKardia, Inc. (NASDAQ:MYOK) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Compani...
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $200,000,000 in shares of its common stock. MyoKardia expects to grant the underwriters a 30-day option to purchase up to $30,000,000 in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data for its investigational drug, mavacamten, from the company’s PIONEER open-label extension (OLE) study. The PIONEER-OLE study enrolled a total of thirteen patients who previously completed the Phase 2 PIONEER-HCM trial. These data reflect the longest duration of mavacamten treatment reported to date. Mavacamten is being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (oHCM), in an ongoing Phase 3 pivotal trial, known as EXPLORER-HCM. Patients with oHCM are at an increased risk of heart failure, atrial fibrillation, stroke and death, including sudden cardiac death. There are an estimated 410,000 people with oHCM in the United States, with approximately 65,000 currently diagnosed and seeking medical attention. The EXPLORER-HCM trial is enrolling 220 patients with oHCM. Patients will be randomized 1:1 to receive mavacamten or placebo for 30 weeks with a primary endpoint of clinical response. EXPLORER-HCM topline data is expected in the second half of 2020, with the completion of enrollment expected in the second half of this year.